Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients
NCT00558493 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2012-07-26
Summary
A multi-center and open study to compare the safety and effectiveness of switching treatment from lamivudine to clevudine for 24 weeks.
Conditions
Interventions
- DRUG
-
Clevudine
clevudine 30 mg qd for 24 seeks
Sponsors & Collaborators
-
Bukwang Pharmaceutical
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
Countries
- South Korea
Study Locations
More Related Trials
-
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
NCT00313261 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV
NCT00501124 ·Status: COMPLETED ·Phase: PHASE4
-
An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
NCT01264354 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
NCT00362700 ·Status: TERMINATED ·Phase: PHASE2
-
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
NCT01264133 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV
NCT00313287 ·Status: TERMINATED ·Phase: PHASE3
-
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.
NCT00044135 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
NCT00305019 ·Status: TERMINATED ·Phase: PHASE2
-
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
NCT00132652 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV
NCT00313274 ·Status: TERMINATED ·Phase: PHASE3
-
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
NCT00823342 ·Status: TERMINATED ·Phase: PHASE3
-
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
NCT00625339 ·Status: COMPLETED ·Phase: PHASE4
-
Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B
NCT01270165 ·Status: UNKNOWN ·Phase: PHASE3
-
Long-Term Lamivudine Therapy for Chronic Hepatitis B
NCT00120354 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B
NCT00672867 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Optimizing Research of Lamivudine Therapy
NCT01088009 ·Status: COMPLETED ·Phase: PHASE4
-
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
NCT00641082 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
NCT00895596 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study
NCT01804387 ·Status: UNKNOWN ·Phase: PHASE4
-
Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
NCT01013272 ·Status: COMPLETED ·Phase: NA
-
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
NCT02482272 ·Status: UNKNOWN ·Phase: PHASE4
-
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
NCT00823550 ·Status: UNKNOWN ·Phase: PHASE4
-
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
NCT00124241 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
NCT00057265 ·Status: COMPLETED ·Phase: PHASE3
-
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
NCT00625560 ·Status: COMPLETED ·Phase: PHASE4